October 8, 2010 – Siemens PETNET Solutions has expanded its imaging biomarker capabilities in Nottingham, England and can now produce new biomarkers as investigational medicine products (IMP) in the United Kingdom.
The IMPs include a hypoxic agent that can identify tumor tissues with low oxygen supply and an amyloid agent for PET imaging of ß-amyloid deposits in the brain.
For more information: www.siemens.com/healthcare
July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...
July 30, 2024 
July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...
July 25, 2024 
July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...
July 25, 2024 
June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...
June 21, 2024 
June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...
June 14, 2024 
June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 14, 2024 
June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...
June 13, 2024 
June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 13, 2024 
June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...
June 12, 2024 
June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...
June 11, 2024